Neurocrine Biosciences (NBIX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $135.71, -0.91% vs the prior close of $136.95.
- Volume 1.08M shares, 0.8x its 50-day average.
- New SEC filings: SCHEDULE 13G/A (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
NBIX dips 0.9% to $135.71. Closed at $135.71, -0.91% vs the prior close of $136.95. Day range $135.55β$138.20, opened at $137.86.
NBIX daily analysis β what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 β NBIX dips 0.9% to $135.71
- Closed at $135.71, -0.91% vs the prior close of $136.95. Day range $135.55β$138.20, opened at $137.86.
- Volume was 1.08M shares, 0.8x its 50-day average of 1.27M.
- Price is -9.1% vs its 50-day average ($149.26) and -7.7% vs its 200-day average ($147.04).
- 52-week range $122.14β$186.12; today's close sits at 21% of that range, 27.1% below the 52-week high.
Oct 15, 2026 β NBIX rises 0.8% to $136.95
- Closed at $136.95, +0.77% vs the prior close of $135.91. Day range $135.55β$138.23, opened at $137.26.
- Volume was 1.38M shares, 1.1x its 50-day average of 1.27M.
- Price is -8.5% vs its 50-day average ($149.74) and -6.9% vs its 200-day average ($147.06).
- 52-week range $122.14β$186.12; today's close sits at 23% of that range, 26.4% below the 52-week high.
Oct 14, 2026 β NBIX rises 0.6% to $135.91
- Closed at $135.91, +0.58% vs the prior close of $135.13. Day range $132.25β$136.57, opened at $133.94.
- Volume was 1.51M shares, 1.2x its 50-day average of 1.26M.
- Price is -9.5% vs its 50-day average ($150.23) and -7.6% vs its 200-day average ($147.10).
- 52-week range $122.14β$186.12; today's close sits at 22% of that range, 27.0% below the 52-week high.
Oct 13, 2026 β NBIX slides 4.4% to $135.13, a 3-month low
- Closed at $135.13, -4.41% vs the prior close of $141.37. Day range $134.89β$139.93, opened at $139.60.
- Volume was 1.57M shares, 1.2x its 50-day average of 1.26M.
- Price is -10.4% vs its 50-day average ($150.84) and -8.2% vs its 200-day average ($147.15).
- 52-week range $122.14β$186.12; today's close sits at 20% of that range, 27.4% below the 52-week high.
Oct 12, 2026 β NBIX dips 0.8% to $141.37
- Closed at $141.37, -0.75% vs the prior close of $142.44. Day range $140.89β$143.63, opened at $142.37.
- Volume was 1.09M shares, 0.8x its 50-day average of 1.33M.
- Price is -6.7% vs its 50-day average ($151.46) and -4.0% vs its 200-day average ($147.20).
- 52-week range $122.14β$186.12; today's close sits at 30% of that range, 24.0% below the 52-week high.
Oct 9, 2026 β NBIX rises 0.8% to $142.44
- Closed at $142.44, +0.84% vs the prior close of $141.25. Day range $140.02β$143.55, opened at $141.33.
- Volume was 1.02M shares, 0.8x its 50-day average of 1.35M.
- Price is -6.3% vs its 50-day average ($151.97) and -3.3% vs its 200-day average ($147.23).
- 52-week range $122.14β$186.12; today's close sits at 32% of that range, 23.5% below the 52-week high.
Oct 8, 2026 β NBIX dips 1.5% to $141.25
- Closed at $141.25, -1.55% vs the prior close of $143.47. Day range $140.34β$143.02, opened at $142.88.
- Volume was 1.24M shares, 0.9x its 50-day average of 1.35M.
- Price is -7.6% vs its 50-day average ($152.83) and -4.1% vs its 200-day average ($147.26).
- 52-week range $122.14β$186.12; today's close sits at 30% of that range, 24.1% below the 52-week high.
Oct 7, 2026 β NBIX dips 1.4% to $143.47
- Closed at $143.47, -1.40% vs the prior close of $145.51. Day range $143.21β$145.88, opened at $145.33.
- Volume was 1.14M shares, 0.8x its 50-day average of 1.35M.
- Price is -6.6% vs its 50-day average ($153.62) and -2.6% vs its 200-day average ($147.28).
- 52-week range $122.14β$186.12; today's close sits at 33% of that range, 22.9% below the 52-week high.
Oct 6, 2026 β NBIX rises 0.9% to $145.51, 3 up days in a row
- Closed at $145.51, +0.90% vs the prior close of $144.21. Day range $141.39β$145.77, opened at $145.56.
- Volume was 1.45M shares, 1.1x its 50-day average of 1.34M.
- Price is -5.8% vs its 50-day average ($154.41) and -1.2% vs its 200-day average ($147.27).
- 52-week range $122.14β$186.12; today's close sits at 37% of that range, 21.8% below the 52-week high.
- That makes 3 straight gains.
Oct 5, 2026 β NBIX rises 0.7% to $144.21
- Closed at $144.21, +0.72% vs the prior close of $143.18. Day range $142.48β$146.92, opened at $142.94.
- Volume was 1.75M shares, 1.3x its 50-day average of 1.33M.
- Price is -7.0% vs its 50-day average ($155.02) and -2.1% vs its 200-day average ($147.25).
- 52-week range $122.14β$186.12; today's close sits at 34% of that range, 22.5% below the 52-week high.
Oct 2, 2026 β NBIX rises 1.8% to $143.18
- Closed at $143.18, +1.76% vs the prior close of $140.71. Day range $140.36β$144.56, opened at $141.41.
- Volume was 1.65M shares, 1.2x its 50-day average of 1.32M.
- Price is -8.0% vs its 50-day average ($155.65) and -2.8% vs its 200-day average ($147.27).
- 52-week range $122.14β$186.12; today's close sits at 33% of that range, 23.1% below the 52-week high.
NBIX latest news & SEC filings
Every SEC filing by or about NBIX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 Β· Form SCHEDULE 13G/A β Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 7, 2026 Β· Form 3 β New insider holdings
Initial insider ownership statement (Form 3) β a new director, officer or 10% owner disclosed their holdings
Sep 28, 2026 Β· Form 8-K β Major event / current report
Current report β a filing companies must make within 4 business days of a major event
- Item 5.02 β Change in directors or officers (appointment, departure or pay).
Sep 15, 2026 Β· Form 4 β Insider trade
Insider trade report (Form 4) β a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 15, 2026 Β· Form 4 β Insider trade
Insider trade report (Form 4) β a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 15, 2026 Β· Form 4 β Insider trade
Insider trade report (Form 4) β a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 15, 2026 Β· Form 4 β Insider trade
Insider trade report (Form 4) β a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 15, 2026 Β· Form 4 β Insider trade
Insider trade report (Form 4) β a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 31, 2026 Β· Form S-8 β Employee share plan registration
Registration of shares for employee stock plans (S-8)
Jul 31, 2026 Β· Form 8-K/A β Current report (amended)
Amended current report
- Exhibits / financial statements only (Item 9.01).
Jul 31, 2026 Β· Form 10-Q β Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $959.00M (prior year $687.50M) (+39.5% vs Jun 30, 2025)
- Net income: $144.40M (prior year $107.50M) (+34.3% vs Jun 30, 2025)
- Diluted EPS: $1.39 (prior year $1.06) (+31.1% vs Jun 30, 2025)
Jul 30, 2026 Β· Form 8-K β Major event / current report
Current report β a filing companies must make within 4 business days of a major event
- Item 2.02 β Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 Β· Form SCHEDULE 13G/A β Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade NBIX
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Feb 11, 2026, Oct 28, 2025. Based on that rhythm, the next report is likely around Oct 29, 2026 β an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.32% (largest 4.4%).
- Liquidity: about 1.42M shares (β$192.55M) trade per day on average.
- 52-week position: $135.71 vs a range of $122.14β$186.12 (21% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Matt Abernethy sold 2,311 shares on Sep 14, 2026.
- Latest filings: 8-K Sep 28, 2026; 10-Q Jul 31, 2026; 8-K Jul 30, 2026.
- Share count: 101.65M shares outstanding (Jul 22, 2026), +2.5% vs a year earlier.
- Listing: Nasdaq Β· industry: Biological Products, (No Diagnostic Substances).
NBIX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 137.86 | 138.20 | 135.55 | 135.71 | 1.08M |
| Oct 15, 2026 | 137.26 | 138.23 | 135.55 | 136.95 | 1.38M |
| Oct 14, 2026 | 133.94 | 136.57 | 132.25 | 135.91 | 1.51M |
| Oct 13, 2026 | 139.60 | 139.93 | 134.89 | 135.13 | 1.57M |
| Oct 12, 2026 | 142.37 | 143.63 | 140.89 | 141.37 | 1.09M |
| Oct 9, 2026 | 141.33 | 143.55 | 140.02 | 142.44 | 1.02M |
| Oct 8, 2026 | 142.88 | 143.02 | 140.34 | 141.25 | 1.24M |
| Oct 7, 2026 | 145.33 | 145.88 | 143.21 | 143.47 | 1.14M |
| Oct 6, 2026 | 145.56 | 145.77 | 141.39 | 145.51 | 1.45M |
| Oct 5, 2026 | 142.94 | 146.92 | 142.48 | 144.21 | 1.75M |
| Oct 2, 2026 | 141.41 | 144.56 | 140.36 | 143.18 | 1.65M |
| Oct 1, 2026 | 140.94 | 143.74 | 139.61 | 140.71 | 2.05M |
| Sep 30, 2026 | 138.33 | 142.91 | 137.63 | 141.84 | 1.85M |
| Sep 29, 2026 | 138.26 | 141.07 | 136.31 | 138.35 | 1.50M |
| Sep 28, 2026 | 137.76 | 140.59 | 136.78 | 140.44 | 1.42M |
| Sep 25, 2026 | 138.94 | 138.94 | 137.02 | 138.40 | 1.17M |
| Sep 24, 2026 | 138.54 | 140.63 | 137.00 | 138.94 | 1.17M |
| Sep 23, 2026 | 141.97 | 142.25 | 139.32 | 139.49 | 1.75M |
| Sep 22, 2026 | 144.17 | 144.26 | 141.78 | 142.25 | 1.21M |
| Sep 21, 2026 | 146.15 | 146.26 | 143.45 | 143.96 | 1.39M |
About Neurocrine Biosciences
Neurocrine Biosciences (NBIX) is listed on the Nasdaq and classified by the SEC under βBiological Products, (No Diagnostic Substances)β. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 914475.
NBIX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Kevin Charles Gorman | Director | Sep 15, 2026 |
| Kyle Gano | Chief Executive Officer | Sep 15, 2026 |
| Gary A Lyons | Director | May 29, 2026 |
| George J Morrow | Director | May 29, 2026 |
| Johanna Mercier | Director | May 29, 2026 |
| Leslie V Norwalk | Director | Jul 30, 2026 |
| Christine A Poon | Director | May 29, 2026 |
| Richard F Pops | Director | May 29, 2026 |
| William H Rastetter | Director | May 29, 2026 |
| Stephen A Sherwin | Director | Sep 3, 2026 |
| Shalini Sharp | Director | May 29, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Matt Abernethy | Chief Financial Officer | Sep 15, 2026 |
| Eric Benevich | Chief Commercial Officer | Sep 15, 2026 |
| David W. Boyer | Chief Corp. Affairs Officer | Sep 15, 2026 |
| Julie Cooke | Chief Human Resources Officer | Sep 15, 2026 |
| Ingrid Delaet | Chief Regulatory Officer | Sep 15, 2026 |
| Kyle Gano | Chief Executive Officer | Sep 15, 2026 |
| Sanjay Chandru Keswani | Chief Medical Officer | Sep 15, 2026 |
| Darin Lippoldt | Chief Legal Officer | Sep 15, 2026 |
| Jude Onyia | Chief Scientific Officer | Sep 15, 2026 |
| Andrew Ratz | Chief Technical Operations Off | Mar 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 14, 2026 | Matt Abernethy | Sale | 2,311 | $157.20 |
| Sep 14, 2026 | Matt Abernethy | Sale | 2,311 | $157.20 |
| Sep 14, 2026 | Matt Abernethy | Sale | 2,311 | $157.20 |
| Sep 14, 2026 | Matt Abernethy | Sale | 2,311 | $157.20 |
| Sep 14, 2026 | David W. Boyer | Sale | 826 | $157.45 |
| Sep 14, 2026 | David W. Boyer | Sale | 826 | $157.45 |
| Sep 14, 2026 | David W. Boyer | Sale | 826 | $157.45 |
| Sep 14, 2026 | David W. Boyer | Sale | 826 | $157.45 |
| Sep 9, 2026 | Eric Benevich | Sale | 2,154 | $154.61 |
| Sep 9, 2026 | Eric Benevich | Sale | 2,154 | $154.61 |
| Sep 9, 2026 | Eric Benevich | Sale | 2,154 | $154.61 |
| Sep 9, 2026 | Eric Benevich | Sale | 2,154 | $154.61 |
| Jul 28, 2026 | Leslie V Norwalk | Sale | 1,250 | $182.01 |
| Jul 28, 2026 | Leslie V Norwalk | Sale | 1,250 | $182.01 |
| Jul 28, 2026 | Leslie V Norwalk | Sale | 1,250 | $182.01 |
NBIX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $2.86B | $478.60M | 4.67 | $782.70M |
| Dec 31, 2024 | $2.36B | $341.30M | 3.29 | $595.40M |
| Dec 31, 2023 | $1.89B | $249.70M | 2.47 | $389.90M |
| Dec 31, 2022 | $1.49B | $154.50M | 1.56 | $339.40M |
| Dec 31, 2021 | $1.13B | $89.60M | 0.92 | $256.50M |
Latest balance sheet: total assets $5.36B, total liabilities $1.67B, cash $332.40M (as of Jun 30, 2026).
NBIX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $185.50 |
| May 5, 2026 | 8-K Item 2.02 (results) | $135.06 |
| Feb 11, 2026 | 8-K Item 2.02 (results) | $137.44 |
| Oct 28, 2025 | 8-K Item 2.02 (results) | $147.38 |
| Jul 30, 2025 | 8-K Item 2.02 (results) | $136.76 |
| May 5, 2025 | 8-K Item 2.02 (results) | $109.75 |
| Feb 6, 2025 | 8-K Item 2.02 (results) | $150.51 |
| Oct 30, 2024 | 8-K Item 2.02 (results) | $124.33 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | β |
| May 1, 2024 | 8-K Item 2.02 (results) | β |
| Feb 7, 2024 | 8-K Item 2.02 (results) | β |
| Oct 31, 2023 | 8-K Item 2.02 (results) | β |
Related stocks Β· Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on NBIX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.